Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

abstract：:Childhood leukemia is the commonest form of childhood cancer and represents clonal proliferation of transformed hemopoietic cells as a result of genetic changes. Molecular characterization of these changes, in particular chromosomal translocations, has yielded a wealth of information on the mechanisms of leukemogenesi...

journal_title：Hematological oncology

authors： Ma SK,Wan TS,Chan LC

更新日期：1999-09-01 00:00:00

abstract：:B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD patho...

journal_title：Hematological oncology

authors： Vakiani E,Basso K,Klein U,Mansukhani MM,Narayan G,Smith PM,Murty VV,Dalla-Favera R,Pasqualucci L,Bhagat G

更新日期：2008-12-01 00:00:00

abstract：:Post-transplant lymphoproliferative disorders (PTLD) are a major problem in transplant medicine. So far, the insights into pathogenesis and potentially druggable pathways in PTLD remain scarce. We investigated a cohort of PTLD patients, consisting of both polymorphic (n = 3) and monomorphic (n = 19) B-cell lymphoproli...

journal_title：Hematological oncology

authors： Menter T,Dickenmann M,Juskevicius D,Steiger J,Dirnhofer S,Tzankov A

更新日期：2017-06-01 00:00:00

abstract：:Sixty-five cases of malignant lymphoma of the nose, paranasal sinuses and hard palate were retrospectively analysed to identify the presence or absence of angiocentric lesions. We observed that the 23 patients with angiocentric lesions had a worse prognosis with a shorter duration of response and also a shorter durati...

journal_title：Hematological oncology

authors： Aviles A,Rodriguez L,Guzman R,Talavera A,Garcia EL,Diaz-Maqueo JC

更新日期：1992-05-01 00:00:00

abstract：:The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...

journal_title：Hematological oncology

authors： Cotter FE

更新日期：1997-02-01 00:00:00

abstract：:Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constit...

journal_title：Hematological oncology

authors： Krashin E,Ellis M,Cohen K,Viner M,Neumark E,Rashid G,Ashur-Fabian O

更新日期：2018-04-01 00:00:00

abstract：:We have collected, by an active retrospective survey, all the cases of hematologic malignancies (HM) newly diagnosed during the time period 1974-1993 in the resident population of Sardinia. Diagnosis was deemed valid, after consultation of clinical records, in more than 90% of the 7264 collected cases. The number of n...

journal_title：Hematological oncology

authors： Broccia G,Deplano W,Dessalvi P,Giannico B,Luxi G,Chessa E,Murru A

更新日期：2004-09-01 00:00:00

abstract：:Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the ...

journal_title：Hematological oncology

authors： Ataei S,Hadjibabaie M,Moslehi A,Taghizadeh-Ghehi M,Ashouri A,Amini E,Gholami K,Hayatshahi A,Vaezi M,Ghavamzadeh A

更新日期：2015-06-01 00:00:00

abstract：:The expression of two membrane antigens identified by the monoclonal antibodies (McAb) My9 and 3C5 has been investigated in cells from 80 acute leukemias. My9 was positive in the blasts of 33 out of the 38 (87 per cent) cases of acute myeloid leukemia (AML) tested, regardless of FAB subtype, and in 13 of 18 (72 per ce...

journal_title：Hematological oncology

authors： Matutes E,Rodriguez B,Polli N,Tavares de Castro J,Parreira A,Andrews C,Griffin JD,Tindle RW,Catovsky D

更新日期：1985-07-01 00:00:00

abstract：:Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patients with initial le...

journal_title：Hematological oncology

authors： Barbui T,Bassan R,Chisesi T,Battista R,Cortelazzo S,Rodeghiero F,Capnist G,D'Emilio A,Viero P,Dini E

更新日期：1985-01-01 00:00:00

abstract：:Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...

journal_title：Hematological oncology

authors： Sekine L,Morais VD,Lima KM,Onsten TG,Ziegelmann PK,Ribeiro RA

更新日期：2015-12-01 00:00:00

abstract：:Acute myeloid leukaemia is a disease with unfavourable prognosis. The significance of various prognostic parameters is not fully understood. We studied 293 patients to examine the influence of ethnicity and molecular markers. The median survival for all patients was correlated with age, white blood cell count and kary...

journal_title：Hematological oncology

authors： Goldschmidt N,Cohen SB,Gatt ME,Safrai M,Rund D

更新日期：2014-06-01 00:00:00

abstract：:In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...

journal_title：Hematological oncology

authors： Liu A,Takahashi M,Toba K,Zheng Z,Hashimoto S,Nikkuni K,Furukawa T,Koike T,Aizawa Y

更新日期：1999-12-01 00:00:00

abstract：:Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...

journal_title：Hematological oncology

authors： Parker D,Alison DL,Barnard DL,Child JA,Dovey G,Farish J,Norfolk DR,O'Brien CJ,Parapia LA,Sharp J

更新日期：1994-01-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) are a subset of multifunctional stem cells with self-renewal and multidirectional differentiation properties that play a pivotal role in tumor progression. MSCs are reported to exert biological functions by secreting specialized vesicles, known as exosomes, with tumor cells. Exosomes part...

journal_title：Hematological oncology

authors： Lyu T,Zhang B,Li M,Jiao X,Song Y

更新日期：2020-08-27 00:00:00

abstract：:Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B-cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate...

journal_title：Hematological oncology

authors： Rueda A,Sabin P,Rifá J,Llanos M,Gómez-Codina J,Lobo F,García R,Herrero J,Provencio M,Jara C,Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL).

更新日期：2008-03-01 00:00:00

abstract：:The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...

journal_title：Hematological oncology

authors： Agarwal S,Gopalakrishnan S,Mensing S,Potluri J,Hayslip J,Kirschbrown W,Friedel A,Menon R,Salem AH

更新日期：2019-10-01 00:00:00

abstract：:Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first a...

journal_title：Hematological oncology

authors： Akahoshi Y,Kimura SI,Gomyo A,Hayakawa J,Tamaki M,Harada N,Kusuda M,Kameda K,Ugai T,Wada H,Ishihara Y,Kawamura K,Sakamoto K,Sato M,Terasako-Saito K,Kikuchi M,Nakasone H,Kako S,Kanda Y

更新日期：2018-02-01 00:00:00

abstract：:We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...

journal_title：Hematological oncology

authors： Richardson DS,Tighe M,Cull G,Johnson SA,Phillips MJ

更新日期：1994-05-01 00:00:00

abstract：:Adult T-cell leukemia-lymphoma (ATLL) is a distinct clinicopathologic entity etiologically linked to HTLV-I infection. We have identified five cases of retrovirus-associated ATLL among Hawaii-born first generation offspring (nisei) of migrant Japanese. Four patients were offspring of migrant Japanese (issei) who emigr...

journal_title：Hematological oncology

authors： Yanagihara ET,Nakamura J,Kimura L,Oishi N

更新日期：1989-03-01 00:00:00

abstract：:The cause of myelosuppression in hairy cell leukemia (HCL) has been ascribed to a reduction of the circulating progenitor cell (CPC) compartment and to suppression of hematopoiesis by TNF-alpha. The present study was performed to evaluate the inhibitory effect of hairy cells (HCs) and a possible lack of hematopoietic ...

journal_title：Hematological oncology

authors： Gasché C,Reinisch W,Schwarzmeier JD

更新日期：1993-03-01 00:00:00

abstract：:Bone marrow (BM) is accepted as the tissue of choice for the detection of monoclonal populations in leukemias and lymphomas; however, obtaining BM can be painful and traumatic for the patients. Although it is possible to detect clonality in peripheral blood (PB) samples, there are no reports comparing the results obse...

journal_title：Hematological oncology

authors： Leal E,Esparza-Flores MA,López-Guido B,Aguilar-Luna C,Aguilar-López L,Jaloma-Cruz AR,Medina C,Barros-Núñez P

更新日期：2003-03-01 00:00:00

abstract：:Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

journal_title：Hematological oncology

authors： Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

更新日期：2018-10-01 00:00:00

abstract：:In the last four years we established five long term cultures from tumor material of Hodgkin's disease. The in vitro cells have malignant characteristics and represent the in vivo H- and SR-cells. Common immunological, functional and morphological assays did not characterize the in vitro cells to be a known cell type ...

journal_title：Hematological oncology

authors： Diehl V,Burrichter H,Schaadt M,Kirchner HH,Fonatsch C,Stein H,Gerdes J,Heit W,Ziegler A

更新日期：1983-04-01 00:00:00

abstract：:High-dose chemotherapy (HDCT) has a consolidated role in the treatment of patients with refractory or relapsed Hodgkin lymphoma (HL). We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Trea...

journal_title：Hematological oncology

authors： Cocorocchio E,Peccatori F,Vanazzi A,Piperno G,Calabrese L,Botteri E,Travaini L,Preda L,Martinelli G

更新日期：2013-03-01 00:00:00

abstract：:Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational stud...

journal_title：Hematological oncology

authors： Klener P,Fronkova E,Belada D,Forsterova K,Pytlik R,Kalinova M,Simkovic M,Salek D,Mocikova H,Prochazka V,Blahovcova P,Janikova A,Markova J,Obr A,Berkova A,Kubinyi J,Vaskova M,Mejstrikova E,Campr V,Jaksa R,Kodet R,

更新日期：2018-02-01 00:00:00

abstract：:The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers,...

journal_title：Hematological oncology

authors： Peña C,Russo M,Martinez V,Cabrera ME

更新日期：2019-02-01 00:00:00

abstract：:Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

journal_title：Hematological oncology

authors： Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

更新日期：1989-11-01 00:00:00

abstract：:There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...

journal_title：Hematological oncology

authors： Wang B,Ren C,Zhang W,Ma X,Xia B,Sheng Z

更新日期：2013-03-01 00:00:00

abstract：:Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. It has been used as an alternative therapy in the hematopoietic stem cell transplant (HSCT) setting in patients who can't tolerate trimethoprim-sulfamethoxazole. The Sulfone syndrome is not a well-known sequela...

journal_title：Hematological oncology

authors： Abidi MH,Kozlowski JR,Ibrahim RB,Peres E

更新日期：2006-09-01 00:00:00